Clinical Trial

A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The main purpose of this study is to determine if participants who previously took donanemab get clinical benefit when they receive annual doses. For each participant, the study will last up to 2.5 years and will include 6 visits.
Protocol Amendment History 3 changes
critical Recruitment opened 2026-06-27
notable Trial sites expanded: 53 -> 58 locations 2026-06-27
minor Completion moved earlier: 2029-12 -> 2029-09 2026-06-27
Trial Details
NCT Number NCT07602582
Lead Sponsor Eli Lilly and Company
Conditions Alzheimer Disease, Dementia, Plaque, Amyloid
Enrollment 550 participants
Start Date 2026-05-22
Primary Completion 2029-09 (estimated)
Study Completion 2029-09 (estimated)
Updated on ClinicalTrials.gov 2026-07-07